Luis Hernandez Vazquez, MD
Endocrinology, Diabetes & Metabolism · Hatillo, PRNPI 1407126675
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,650 of the $20,313 with a category attached, or 77.0%. AstraZeneca accounts for 89.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $9,705 and has fallen 98.2% since, to $174 in 2025.
Across 132 payments — averaging $153.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$18K
- Eli Lilly Export S.A. Puerto Rico Branch$576
- Medtronic$451
- Boehringer Ingelheim$352
- Amgen$205
- Sanofi-aventis U.S. LLC$157
- plus $490 from 8 others
Across 22 payments — averaging $4887.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly Export S.A. Puerto Rico Branch$89K
- Eli Lilly$14K
- AbbVie$5K
What the payments were for
- Speaking & faculty fees$15,65077%
- Travel & lodging$1,3677%
- Food & beverage$3,27816%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $18,081 |
| Eli Lilly Export S.A. Puerto Rico Branch | 23 | $576 |
| Medtronic | 4 | $451 |
| Boehringer Ingelheim | 18 | $352 |
| Amgen | 8 | $205 |
| Sanofi-aventis U.S. LLC | 9 | $157 |
| Dexcom, Inc. | 5 | $113 |
| Merck | 5 | $96 |
| Abbott | 4 | $89 |
| PBG Puerto Rico LLC | 3 | $63 |
| Johnson & Johnson | 1 | $53 |
| Lilly USA, LLC | 2 | $31 |
| AbbVie | 1 | $24 |
| Novo Nordisk | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$16,912
- Minimed 670G System$414
- SYMBICORT$125
How this compares
$20,313 in reported general payments places this provider in the 85th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 259 | $167,732 |
| JentaduetoLinagliptin/Metformin Hcl | 146 | $95,989 |
| TrulicityDulaglutide | 90 | $89,150 |
| TradjentaLinagliptin | 132 | $80,307 |
| GlyxambiEmpagliflozin/Linagliptin | 86 | $76,790 |
| Xigduo XrDapaglifloz Propaned/Metformin | 92 | $65,640 |
| FarxigaDapagliflozin Propanediol | 84 | $64,058 |
| OzempicSemaglutide | 61 | $61,191 |
| SynthroidLevothyroxine Sodium | 916 | $60,850 |
| JardianceEmpagliflozin | 71 | $55,575 |
| Jentadueto XrLinagliptin/Metformin Hcl | 87 | $51,338 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 65 | $50,854 |
| MounjaroTirzepatide | 47 | $50,612 |
| JanumetSitagliptin Phos/Metformin Hcl | 69 | $43,409 |
| SynjardyEmpagliflozin/Metformin Hcl | 64 | $40,753 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Jentadueto, Tradjenta, Glyxambi, Jardiance | $352 | $619,337910 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30, Humalog Mix 75-25 | $31 | $176,760480 claims |
| MerckJanumet, Januvia, Janumet Xr | $96 | $96,035149 claims |
| AstraZenecaFarxiga | $18,081 | $64,05884 claims |
| Novo NordiskOzempic, Novolog | $23 | $63,60872 claims |
| AbbVieSynthroid | $24 | $60,850916 claims |
| Sanofi-aventis U.S. LLCLantus | $157 | $20,117199 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in Hatillo
- Gabriel Mora OsoriaHatillo$9K
- Nicolas Cruz DardizHatillo$6K
- Jose Garcia MateoPonce$945K
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Alex Gonzalez BossoloSan Juan$110K
- Michelle Mangual GarciaSan Juan$87K
- Meliza Martinez RodriguezSan Juan$80K
- Milliette Alvarado SantiagoRio Piedras$75K
- Altagracia Alcantara GonzalezBayamon$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.